Molecular dynamic studies of Lanifibranor showed that it can be a promising drug candidate in treating NASH, that fully activates PPARα, and PPARδ whereas partially activate PPARγ. Here, PPARA is linked to metabolic dysfunction-associated steatohepatitis.